Valuation of the quality attributes of tomato for fresh market: a study with CEAGESP wholesalers

The great variation in the value of tomato from the same variety group, same classification and on the same day of marketing, registered by the Terminal Market of CEAGESP, were related to the difference in quality among the attributes of those fruits. The main goal of this work was to create a tool for the evaluation of the quality attributes considered important for tomatoes and from the assessment of these attributes target the most relevant for the difference in value practiced during commercialization at CEAGESP. Firstly, based on the interview with the agents of commercialization of tomatoes at CEAGESP, the main attributes seen by them, which determine the quality of tomato, were raised. Based on those answers, in a second stage, a gauge visual quality assessment was created to be used as a differential tool in the process of decision making. In a third stage, the maximum and minimum price for three classifications (big, medium and minute) were raised for lots of tomato in the same day and their quality attributes were evaluated for two systems: system I - the quality attributes were evaluated, based on banknotes of performance according to the loading gauge visual, and for system II - in addition to the assessment by notes according to the loading gauge visual, the frequency of occurrence of the attribute in a lot of tomato was measured. The attributes that determine the quality of tomato, according to the tomatoes commercialization agents from CEAGESP, are: size (type or size), fruit color, absence of defects, durability, packaging and flavor. The most important attributes to explain the variation of prices assessed by the system I are packaging that are suitable to be palletized and packaging that provides an appropriate pile, on the other hand, for system II, these attributes are: fruit without superficial skin damage and adequate protection of the package against mechanical injuries.A grande variação no valor do tomate de mesa, do mesmo grupo varietal, mesma classificação e no mesmo dia de comercialização, no mercado atacadista da CEAGESP, tem entre suas causas mais importantes a diferença de qualidade nos atributos destes frutos. O objetivo deste trabalho foi criar uma ferramenta de avaliação dos atributos de qualidade considerados importantes para o tomate de mesa e, a partir da avaliação, apontar os mais relevantes na diferença de valor praticado na comercialização da CEAGESP. Primeiramente, foram levantados os principais atributos que determinam a qualidade do tomate de mesa a partir de entrevista com agentes de comercialização de tomate da CEAGESP. A partir deste levantamento, foi criado um gabarito de avaliação visual da qualidade. Por fim, foram levantados os lotes de tomate de mesa de preço máximo e os de preço mínimo para três classificações (graúdo, médio e miúdo) comercializados no mesmo dia, avaliando-se os seus atributos de qualidade por dois sistemas: sistema I - avaliação dos atributos de qualidade por meio de notas de desempenho de acordo com o gabarito, e o sistema II - levantamento da frequência de ocorrência de cada atributo avaliado no lote de tomate. Os atributos que determinam a qualidade do tomate, segundo os agentes de comercialização de tomate da CEAGESP, são: o tamanho (tipo ou calibre), a coloração do fruto, a ausência de defeitos, durabilidade, embalagem e sabor. Os atributos determinantes na variação de preços avaliados pelo sistema I são embalagens paletizáveis e embalagens que proporcionem um adequado empilhamento, enquanto que, para o sistema II, estes atributos são: frutos sem danos superficiais de casca e proteção adequada da embalagem contra injúrias mecânicas.214219Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq

Non-adiabatic radiative collapse of a relativistic star under different initial conditions

We examine the role of space-time geometry in the non-adiabatic collapse of a star dissipating energy in the form of radial heat flow, studying its evolution under different initial conditions. The collapse of a star with interior comprising of a homogeneous perfect fluid is compared with that of a star filled with inhomogeneous imperfect fluid with anisotropic pressure. Both the configurations are spherically symmetric, however, in the latter case, the physical space $t= constant$ of the configurations is assumed to be inhomogeneous endowed with spheroidal or pseudo-spheroidal geometry. It is observed that as long as the collapse is shear-free, its evolution depends only on the mass and size of the star at the onset of collapse.Comment: To appear in Pramana- j. of physic

Radiating Shear-Free Gravitational Collapse with Charge

We present a new shear free model for the gravitational collapse of a spherically symmetric charged body. We propose a dissipative contraction with radiation emitted outwards. The Einstein field equations, using the junction conditions and an ansatz, are integrated numerically. A check of the energy conditions is also performed. We obtain that the charge delays the black hole formation and it can even halt the collapse.Comment: 22 pages, 9 figures. It has been corrected several typos and included several references. Accepted for publication in GR

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone all individually reduce cardiovascular, kidney, and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known. METHODS: We used data from 2 SGLT2i trials (CANVAS [Canagliflozin Cardiovascular Assessment] and CREDENCE [Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation]), 2 ns-MRA trials (FIDELIO-DKD [Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease] and FIGARO-DKD [Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease]), and 8 GLP-1 RA trials to estimate the relative effects of combination therapy versus conventional care (renin-angiotensin system blockade and traditional risk factor control) on cardiovascular, kidney, and mortality outcomes. Using actuarial methods, we then estimated absolute risk reductions with combination SGLT2i, GLP-1 RA, and ns-MRA in patients with type 2 diabetes and at least moderately increased albuminuria (urinary albumin:creatinine ratio ≥30 mg/g) by applying estimated combination treatment effects to participants receiving conventional care in CANVAS and CREDENCE. RESULTS: Compared with conventional care, the combination of SGLT2i, GLP-1 RA, and ns-MRA was associated with a hazard ratio of 0.65 (95% CI, 0.55–0.76) for major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death). The corresponding estimated absolute risk reduction over 3 years was 4.4% (95% CI, 3.0–5.7), with a number needed to treat of 23 (95% CI, 18–33). For a 50-year-old patient commencing combination therapy, estimated major adverse cardiovascular event–free survival was 21.1 years compared with 17.9 years for conventional care (3.2 years gained [95% CI, 2.1–4.3]). There were also projected gains in survival free from hospitalized heart failure (3.2 years [95% CI, 2.4–4.0]), chronic kidney disease progression (5.5 years [95% CI, 4.0–6.7]), cardiovascular death (2.2 years [95% CI, 1.2–3.0]), and all-cause death (2.4 years [95% CI, 1.4–3.4]). Attenuated but clinically relevant gains in event-free survival were observed in analyses assuming 50% additive effects of combination therapy, including for major adverse cardiovascular events (2.4 years [95% CI, 1.1–3.5]), chronic kidney disease progression (4.5 years [95% CI, 2.8–5.9]), and all-cause death (1.8 years [95% CI, 0.7–2.8]). CONCLUSIONS: In patients with type 2 diabetes and at least moderately increased albuminuria, combination treatment of SGLT2i, GLP-1 RA, and ns-MRA has the potential to afford relevant gains in cardiovascular and kidney event-free and overall survival

The experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people

Background: Children and young people (CYP) with juvenile idiopathic arthritis (JIA) are known to have impaired health-related quality of life (HRQoL), which is improved significantly for many by treatment with methotrexate (MTX). However, a significant proportion of CYP experience difficulties in taking MTX, which may reduce its potential benefits for HRQoL. The aim of this research was to examine how CYP with JIA perceive MTX treatment and how this relates to HRQoL. Methods: CYP aged 8-16 years taking MTX for JIA completed an adapted Parent Adherence Report Questionnaire, which contains 100mm visual analogue scales, to assess difficulty taking MTX, adherence, frequency of negative reactions and helpfulness of MTX. They also completed the Pediatric Quality of Life Inventory (PedsQL) Generic and Rheumatology scales. We collected data on age, gender, JIA course, disease duration, MTX duration of use, route and dose. Number of inflamed and limited joints were indicators of disease severity. Results: 116 CYP participated. Most considered MTX helpful (median 87; interquartile range (IQR) 50.75–98) and reported adherence was high (median 98; IQR 90–100). There was greater variability on scores for difficulty (median 22; IQR 2–69) and frequency of negative reactions (median 14.5; IQR 1.25–80). Mean (S.D.) scores on the PedsQL Physical and Psychosocial subscales were 71.63 (24.02) and 71.78 (19.59) respectively, indicating poorer HRQoL than that reported by healthy children. After controlling for demographic and disease variables, poorer physical HRQoL was significantly accounted for by greater difficulty in taking MTX. Poorer psychosocial HRQoL was significantly accounted for by subcutaneous MTX administration, a lower rating of MTX helpfulness and a greater reported difficulty in taking MTX. Conclusions: Taking MTX for JIA was viewed as helpful by most CYP but HRQoL was poorer in those who reported greater difficulty in taking MTX

Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway

This article has been made available through the Brunel Open Access Publishing Fund - Copyright @ 2009 Orton et al.BACKGROUND: The Epidermal Growth Factor Receptor (EGFR) activated Extracellular-signal Regulated Kinase (ERK) pathway is a critical cell signalling pathway that relays the signal for a cell to proliferate from the plasma membrane to the nucleus. Deregulation of the EGFR/ERK pathway due to alterations affecting the expression or function of a number of pathway components has long been associated with numerous forms of cancer. Under normal conditions, Epidermal Growth Factor (EGF) stimulates a rapid but transient activation of ERK as the signal is rapidly shutdown. Whereas, under cancerous mutation conditions the ERK signal cannot be shutdown and is sustained resulting in the constitutive activation of ERK and continual cell proliferation. In this study, we have used computational modelling techniques to investigate what effects various cancerous alterations have on the signalling flow through the ERK pathway. RESULTS: We have generated a new model of the EGFR activated ERK pathway, which was verified by our own experimental data. We then altered our model to represent various cancerous situations such as Ras, B-Raf and EGFR mutations, as well as EGFR overexpression. Analysis of the models showed that different cancerous situations resulted in different signalling patterns through the ERK pathway, especially when compared to the normal EGF signal pattern. Our model predicts that cancerous EGFR mutation and overexpression signals almost exclusively via the Rap1 pathway, predicting that this pathway is the best target for drugs. Furthermore, our model also highlights the importance of receptor degradation in normal and cancerous EGFR signalling, and suggests that receptor degradation is a key difference between the signalling from the EGF and Nerve Growth Factor (NGF) receptors. CONCLUSION: Our results suggest that different routes to ERK activation are being utilised in different cancerous situations which therefore has interesting implications for drug selection strategies. We also conducted a comparison of the critical differences between signalling from different growth factor receptors (namely EGFR, mutated EGFR, NGF, and Insulin) with our results suggesting the difference between the systems are large scale and can be attributed to the presence/absence of entire pathways rather than subtle difference in individual rate constants between the systems.This work was funded by the Department of Trade and Industry (DTI), under their Bioscience Beacon project programme. AG was funded by an industrial PhD studentship from Scottish Enterprise and Cyclacel

An overview of the design, construction and performance of large area triple-GEM prototypes for future upgrades of the CMS forward muon system

GEM detectors are used in high energy physics experiments given their good spatial resolution, high rate capability and radiation hardness. An international collaboration is investigating the possibility of covering the 1.6 < vertical bar eta vertical bar < 2.4 region of the CMS muon endcaps with large-area triple-GEM detectors. The CMS high-eta area is actually not fully instrumented, only Cathode Strip Chamber (CSC) are installed. The vacant area presents an opportunity for a detector technology able to to cope with the harsh radiation environment; these micropattern gas detectors are an appealing option to simultaneously enhance muon tracking and triggering capabilities in a future upgrade of the CMS detector. A general overview of this feasibility study is presented. Design and construction of small (10cm x 10cm) and full-size trapezoidal (1m x 0.5m) triple-GEM prototypes is described. Results from measurements with x-rays and from test beam campaigns at the CERN SPS is shown for the small and large prototypes. Preliminary simulation studies on the expected muon reconstruction and trigger performances of this proposed upgraded muon system are reported